Prescription Drug Prices Fall 3.1%, Steepest Drop Since 1963

The number behind the victory lap

U.S. prescription drug prices have done something they almost never do. They fell. According to the Bureau of Labor Statistics' Consumer Price Index, prescription drug prices dropped 0.8% from June to July 2026 and were 3.1% lower than a year earlier. That is the steepest year-over-year decline since March 1963.2223 The broader medicinal drugs index, which also counts over-the-counter products, fell 2.7% over the year. It was reported as the largest annual drop on record for that series.25

The White House has turned the figure into a campaign theme. In a September release announcing that its pricing deals now cover every state Medicaid program, the administration called it the largest annual decline in more than 60 years and said prices had fallen in every month of 2026.1 Dr. Mehmet Oz's CMS account repeated the "sharpest drop" line in October.9 President Trump has gone further, saying in September that the U.S. went from the highest drug prices in the world to the lowest.11

The decline is real, and it is unusual. Nearly every independent analysis, though, concludes that the administration is claiming more of it than the evidence supports, and that the index measures less than the headline suggests.

A small discrepancy in the official story

The sources disagree on one detail. The White House says prices fell every month this year.1 Reporting based on the BLS data describes something slightly different: prices did not rise in any month of 2026 and fell in five of the last six.2225 Axios also described it as a stretch of flat or falling prices.23 "Not rising" and "falling every month" are different claims, and the gap shows how hard the numbers are being pushed.

The timing matters too. CBS News reports that drug prices are down 3.9% since peaking in February 2025, shortly after Trump took office for his second term.13 Axios's chart shows year-over-year drug inflation running at 4.6% that same month. The series stayed mostly positive from 2022 through 2025 and only turned negative in 2026.23 The turnaround did happen on Trump's watch. Whether it happened because of him is a separate question.

What the experts credit instead

The expert consensus is unusually consistent. Most health economists quoted across outlets point first to the 2022 Inflation Reduction Act. That Biden-era law gave Medicare the power to negotiate prices, and the first negotiated prices on 10 high-spending drugs took effect on January 1, 2026.2225 Axios reported that those prices were as much as 79% below list.23

Vanderbilt's Stacie Dusetzina told the Associated Press that the administration's most-favored-nation (MFN) policies were still being developed and had not yet reached the payers the index tracks. She said the decline is more likely tied to the IRA's negotiation program.21 Brookings senior fellow Richard Frank said that if he had to bet on the main cause, it would be the IRA.22 USC health economist Geoffrey Joyce agreed that the IRA deserves the policy credit, but added that market forces are driving much of the decline.23

The CPI's method helps explain why Medicare negotiation shows up. The index tracks what pharmacies receive from patients and insurers, including Medicare, and does not capture manufacturer rebates paid after the sale.23 A change in what Medicare pays pharmacies can therefore move the number directly.

Competition is the other major factor. Harvard's Benjamin Rome noted that blockbuster drugs get cheaper when generics arrive, and pointed to Humira biosimilars as an example. Dusetzina cited similar price cuts for Stelara.21 CBS News, citing Brookings, also noted more generics entering the market.13

The White House rejects this account. Spokesperson Kush Desai called crediting the IRA "idiotic and unfounded" and argued that its negotiated prices did not deliver meaningful savings beyond discounts insurers already had.23 Nobody has published an analysis that splits the 3.1% among these causes.2225 Still, the policy most experts credit took effect on January 1, while the administration's MFN programs for federal health plans had not yet taken effect, according to the AP.21 That makes the IRA the more plausible main driver.

Weight-loss drugs: where both sides have a case

GLP-1 obesity and diabetes drugs are the one area where the administration's actions and market forces clearly overlap. Under deals announced in November 2025, Novo Nordisk agreed to sell Ozempic and Wegovy through TrumpRx for $350 a month. Their prices had been roughly $1,000 and $1,350. Eli Lilly's Zepbound was set to fall from more than $1,080 to an average of $346.12 Current TrumpRx listings go lower: Wegovy pens start at $199, the Wegovy pill at $149, and Zepbound at $299.19 A Medicare GLP-1 program launched in July lets eligible beneficiaries get Wegovy, Zepbound and Foundayo with a $50 copay.22 The White House says more than 500,000 seniors have used it and saved $216 million.6

Axios treated the Lilly and Novo deals as a real contributor to the downward pressure, while noting that other forces were already working.23 CBS News pointed out that GLP-1 makers are also cutting prices because competition is heating up.13 The AP added a timing caveat: the Medicare GLP-1 policy started in July, so only one month of it appears in the data.28

The most reasonable reading is that weight-loss drugs are where the administration's deals most clearly lowered visible prices. They are also a market where rival products were already pushing prices down.

Cancer drugs and the international comparison

Cancer medicines show the administration's case at its strongest, and also where it falls short. TrumpRx lists Novartis's blood-cancer drug Rydapt at about $2,909, down from $13,411. Tabrecta, a lung-cancer drug, is listed at about $2,650, down from $11,666.19 NBC News reported that Rydapt's TrumpRx price is less than half the $5,901 charged in France, the next-cheapest country in the comparison.11

An analysis by the health research group KFF found that results like that are not typical. KFF compared 32 brand-name drugs on TrumpRx that have no generic equivalent against prices in 11 other wealthy countries. TrumpRx was cheaper than the foreign average for 17 drugs and more expensive for 15. Only five were the lowest-priced anywhere, while 13 cost more on TrumpRx than in any other country studied.1114 Ozempic costs $349 on TrumpRx, compared with $190 in the next-highest country in KFF's data.14 Enbrel, a rheumatoid arthritis drug, costs $3,354 a month, more than five times the $641 foreign average.11 KFF's Juliette Cubanski called it "a mixed bag."14

This is the clearest problem with Trump's "lowest in the world" claim. When Sen. Bernie Sanders pressed FDA nominee Heidi Overton on it during her September confirmation hearing, she would not say it was true. She pointed instead to the CPI decline.25 Common Dreams cited a 2024 RAND study finding that Americans pay nearly three times what other countries pay for prescription drugs.5

What drugmakers gave up, and what they got

The administration says 26 large drugmakers, covering about 90% of the branded U.S. market, have signed MFN agreements. It projects savings of more than $600 billion.1 The companies are not acting purely out of goodwill. Under the deals, they are exempt from new pharmaceutical tariffs through January 2029.22 That matters because a 100% tariff on patented drugs from large manufacturers took effect on July 31.22 The companies have also pledged about $170 billion for U.S. manufacturing and research.8

The terms of the deals are still secret. NPR contacted Pfizer and 16 other companies that signed agreements, and none would confirm that all of their drugs would be discounted for Medicaid.18 USA Today noted that the administration has not released the terms of the voluntary agreements.16 The White House says TrumpRx has saved patients $700 million but has not explained how it calculated that figure. Sen. Elizabeth Warren has challenged it, noting that the site does not store prescription data.21

Cubanski raised a less obvious risk. As more drugmakers sign deals, they could close the gap between U.S. and foreign prices by raising prices abroad instead of cutting them at home.14

Why patients may not notice

The CPI measures transaction prices for a sample of drugs. It does not track list prices or what any individual pays at the pharmacy, and many insured patients pay fixed copays that do not change when the index falls.2225 Over the same 12 months, hospital services rose 5.2% and physicians' services rose 2.4%.22 Six in 10 adults told KFF they worry about affording their medications, the highest share since KFF began asking in 2018.23 TrumpRx purchases also do not count toward a patient's deductible or copay.14

The decline may not last. Vizient projects pharmaceutical prices will rise 3.54% in 2027, a forecast that does not yet fully account for the new tariffs.22 A federal customs rule is also expected to make drugs imported from Canada much more expensive for many Americans.17 On the other side, Medicare-negotiated prices for 15 more drugs, including Ozempic and Wegovy, take effect in 2027.25

The bottom line

The drop in prescription drug prices is the most important affordability news in health care this year. The administration is using it as evidence that its approach works. A closer look at the data points elsewhere: much of the decline traces to a Biden-era Medicare law the administration continues to carry out, along with ordinary generic competition and a price war among GLP-1 makers that its deals sped up. The White House can fairly claim credit for cheaper cash prices on weight-loss drugs and some cancer drugs. It cannot back up the claim that Americans now pay the lowest drug prices in the world. With the deal terms secret and tariffs threatening the decline, it is too soon to say the trend will hold.